Effector lymphocytes in islet cell autoimmunity

Reviews in Endocrine and Metabolic Disorders

Volumn 4, Issue 3, 2003, Pages 271-280

  Santamaria, Pere ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Apoptosis; Beta cells; Cytotoxic T lymphocytes; Fas; Perforin; TNF; TNFR; Type 1 diabetes

Indexed keywords

FAS ANTIGEN; PERFORIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNITY; CELL DEATH; CELL KILLING; CELL TYPE; CYTOTOXIC T LYMPHOCYTE; DNA DAMAGE; EFFECTOR CELL; EXOCYTOSIS; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PANCREAS ISLET CELL; REVIEW; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ANIMALS; AUTOIMMUNITY; ISLETS OF LANGERHANS; T-LYMPHOCYTES, REGULATORY;

EID: 0042839574     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025156413404     Document Type: Review

References (156)

1. Ji H, Korganow AS, Mangialaio S, Hoglund P, Andre I, Luhder F, Gonzalez A, Poirot L, Benoist C, Mathis D. Different modes of pathogenesis in T-cell-dependent autoimmunity: Clues from two TCR transgenic systems. Immunol Rev 1999;169:139-146.
2. Abiru N, Eisenbarth G. Autoantibodies and autoantigens in type 1 diabetes: Role in pathogenesis, prediction and prevention. Can Journ Diab Car 1999;23:59-65.
3. Henkart PA. Mechanism of lymphocyte-mediated cytotoxicity. Annu Rev Immunol 1985;3:31-58.
4. Ostergaard HL, Kane KP, Mescher MF, Clark WR. Cytotoxic T lymphocyte mediated lysis without release of serine esterase. Nature 1987;330:71-72.
5. Helgason CD, Prendergast JA, Berke G, Bleackley RC. Peritoneal exudate lymphocyte and mixed lymphocyte culture hybridomas are cytolytic in the absence of cytotoxic cell proteinases and perforin. Eur J Immunol 1992;22:3187-190.
6. Rouvier E, Luciani MF, Golstein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 1993;177:195-200.
7. Katz J, Benoist C, Mathis D. Major histocompatibility complex class I molecules are required for the generation of insulitis in non-obese diabetic mice. Eur J Immunol 1993;23:3358-3360.
8. null mice are diabetes and insulitis resistant. Diabetes 1994;43:505-508.
9. Wicker L, Leiter E, Todd J, Renjilian RJ, Peterson E, Fischer PA, Podolin PL, Zijlstra M, Jaenisch R, Peterson LB. β 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes 1994;43:500-504.
10. + T-cells in initiation of insulin-dependent diabetes mellitus. Eur J Immunol 1996;26:1762-1769.
11. + cytotoxic T cells in the destruction of pancreatic beta cells in NOD mice. J Immunol 1994;152:2042-2050.
12. + T cells from non-obese diabetic mice use highly homologous T cell receptor alpha chain CDR3 sequences. J Immunol 1995;154:2494-2503.
13. + T cells expressing identical endogenous TCRα chains. J Immunol 1996;157:4726-4735.
14. Verdaguer J, Schmidt D, Amrani A, Anderson B, Averill N, Santamaria P. Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. J Exp Med 1997;186:1663-1676.
15. DiLorenzo T, Graser T, Ono T, Christianson GJ, Chapman HD, Roopenian DC, Nathenson SG, Serreze DV. MHC class I-restricted T-cells are required for all but end stages of diabetes development and utilize a prevalent T cell receptor a chain gene rearrangement. Proc Natl Acad Sci USA 1998;95:12538-12542.
16. + T cell response against one peptide/MHC complex in autoimmune diabetes. Proc Natl Acad Sci USA 1999;96:9311-9316.
17. Amrani A, Verdaguer J, Serra P, Tafuro S, Tan R, Santamaria P. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 2000;406:739-742.
18. + T-cells from diabetic versus prediabetic NOD.NON-thy-1a donors. Diabetes 1993;42:44-55.
19. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996;85:291-297.
20. Schmidt D, Verdaguer J, Averill N, Santamaria P. A mechanism for the major histocompatibility complex-linked resistance to autoimmunity. J Exp Med 1997;186:1059-1075.
21. + thymocytes by protective MHC class II molecules. J Immunol 1999;162:4627-4636.
22. Delovitch T, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: Immune disregulation gets the NOD. Immunity 1997;7:727-738.
23. + T cells. Diabetes 1996;45:328-336.
24. Kurrer M, Pakala S, Hanson H, Katz J. Beta cell apoptosis in T cell-mediated autoimmune diabetes. Proc Natl Acad Sci USA 1997;94:213-218.
25. + T cells in organ-specific autoimmunity: Emerging targets for therapeutic intervention. Immunity 2002;17:1-20.
26. Fennessy M, Metcalfe K, Hitman GA, Niven M, Biro PA, Tuomilehto J, Tuomilehto-Wolf E. A gene in the HLA class I region contributes to susceptibility to IDDM in the Finnish population. Childhood Diabetes in Finland (DiMe) Study Group. Diabetologia 1994;37:937-944.
27. Honeyman M, Harrison L, Drummond B, Colman P, Tait B. Analysis of families at risk for insulin-dependent diabetes mellitus reveals that HLA antigens influence progression to clinical disease. Mol Med 1995;1:576-582.
28. Tait B, Harrison L, Drummond B, Stewart V, Varney M, Honeyman M. HLA antigens and age at diagnosis of insulin-dependent diabetes mellitus. Hum Immunol 1995;42:116-122.
29. Nejentsev S, Reijonen H, Adojaan B, Kovalchuk L, Sochnevs A, Schwartz EI, Akerblom HK, Ilonen J. The effect of HLA-B allele on the IDDM risk defined by DRB1*04 subtypes and DQB1*0302. Diabetes 1997;46:1888-1892.
30. Nakanishi K, Kobayashi T, Murase T, Naruse T, Nose Y, Inoko H. HLA-A24 and -DQA1*0301 in Japanese insulin-dependent diabetes mellitus: Independent contributions to susceptibility to the disease and additive contributions to acceleration of beta cell destruction. J Clin Endocrinol Metab 1999;84:3721-3725.
31. Bottazzo GF, Dean BM, McNally JM, McKay EH, Swift PGF, Gamble DR. In situ characterization of autoimmune phenomenon: An expression of HLA molecules in the pancreas of diabetic insulinitis. N Engl J Med 1985;313:353-360.
32. Hanninen A, Jalkanen S, Salmi M, Toikkanen S, Nikolakaros G, Simell O. Macrophages, T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. J Clin Invest 1992;90:1901-1908.
33. Itoh N, Hanafusa T, Miyazaki A, Miyagawa J, Yamagata K, Yamamoto K, Waguri M, Imagawa A, Tamura S, Inada M, et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 1993;92:2313-2322.
34. Somoza N, Vargas F, Roura-Mir C, Vives-Pi M, Fernandez-Figueras MT, Ariza A, Gomis R, Bragado R, Marti M, Jaraquemada D. Pancreas in recent onset insulin-dependent diabetes mellitus. J Immunol 1994;153:1360-1377.
35. Sibley RK, Sutherland DER, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. Lab Invest 1985;53:132-144.
36. + T cells from isletitis of graft-recurrent type I diabetes are oligoclonal and show restricted TCR usage. Diabetes 1992;41(suppl. 1): 97A.
37. Santamaria P, Nakhleh RE, Sutherland DER, Barbosa JJ. Isolation and characterization of T lymphocytes infiltrating a human pancreas allograft affected by isletitis and recurrent diabetes. Diabetes 1992;41:53-61.
38. Ohashi P, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, Malissen B, Zinkernagel RM, Hengartner H. Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65:305-317.
39. + T-cell-mediated spontaneous diabetes in neonatal mice. J Immunol 1996;157:978-983.
40. Blanas E, Carbone F, Allison J, Miller J, Heath W. Induction of autoimmune diabetesby oral administration of autoantigen. Science 1996;274:1707-1709.
41. Wong F, Karttunen J, Dumont C, Wen L, Visintin I, Pilip IM, Shastri N, Pamer EG, Janeway CA. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med 1999;9:1026-1031.
42. Amrani A, Serra P, Yamanouchi J, Trudeau JD, Tan R, Elliott JF, Santamaria P. Expansion of the antigenic repertoire of a single T cell receptor upon T-cell activation. J Immunol 2001;167:655-666.
43. Trudeau J, Kelly-Smith C, Verchere B, Finegood D, Santamaria P, Tan R. Autoreactive T cells in peripheral blood predict development of type 1 diabetes. J Clin Invest 2003;111:217-223.
44. Graser R, DiLorenzo T, Wang F, Christianson GJ, Chapman HD, Roopenian DC, Nathenson SG, Serreze DV. Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions. J Immunol 2000;164:3913-3918.
45. + T cell development in TCR Transgenic Nonobese Diabetic (NOD) mice. J Immunol 2000;164:5466-5473.
46. Heath W, Carbone F. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47-64.
47. Carbone F, Bevan M. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 1990;171:377-387.
48. Huang A, Golumbeck P, Ahmadzadeh E, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-965.
49. Sigal L, Crotty S, Andino R, Rock K. Cytotoxic T-cell immunity to virus-infected non-haemotopoietic cells requires presentation of exogenous antigen. Nature 1999;398:77-80.
50. Kurts C, Heath W, Carbone F, Allison J, Miller J, Kosaka H. Constitutive class I-restricted exogenous presentation of self-antigens in vivo. J Exp Med 1996;184:923-930.
51. Albert M, Pearce S, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N. Immature dendritic cells phagocytose apoptotic cells via alphaV-beta-5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998;188:1359-1368.
52. Albert M, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-89.
53. Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, Rugarli C, Manfredi AA. Cutting-edge: Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998;161:4467-4471.
54. Sauter B, Albert M, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-434.
55. Zhang Y, O'Brien B, Trudeau J, Tan R, Santamaria P, Dutz J. In situ beta cell death promotes priming of diabetogenic CD8+ T lymphocytes. J Immunol 2001;168:1466-1472.
56. Trudeau J, Dutz J, Arany E, Hill D, Fieldus W, Finegood D. Neonatal beta-cell apoptosis: A trigger for autoimmune diabetes? Diabetes 2000;49:1-7.
57. Finegood D, Scaglia L, Bonner-Weir S. Dynamics of beta cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes 1995;44:249-256.
58. + T cell helper functions. J Immunol 2000;164:3913-3918.
59. Stuhler G, Walden P. Collaboration of helper and cytotoxic T lymphocytes. Eur J Immunol 1993;23:2279-2286.
60. Grewal I, Xu J, Flavell R. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995;378:617-620.
61. Essen Dv, Kikutani H, Gray D. CD40 ligand-transduced costimulation of T-cells in the development of helper function. Nature 1995;378:620-623.
62. Yang Y, Wilson J. CD40 ligand-dependent T-cell activation: Requirement of B7-CD28 signalling through CD40. Science 1996;273:1862-1865.
63. Grewal I, Foellmer H, Grewal K, Xu J, Hardardottir F, Baron JL, Janeway CA Jr, Flavell RA. Requirement for CD40 ligand in costimulation induction, T-cell activation, and experimental allergic encephalomyelitis. Science 1996;273:1864-1868.
64. + T-helper and a T-killer cell. Nature 1998;393:474-478.
65. Bennett S, Carbone F, Karamalis F, Flavell R, Miller J, Heath W. Help for cytotoxic T-cell responses is mediated by CD40 signalling. Nature 1998;393:478-480.
66. Schoenberger S, Toes R, Voort Evd, Offringa R, Melief C. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-483.
67. Grewal I, Flavell R. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-135.
68. + T cells dissociated from activation of antigen-presenting cells. Immunol 2002;16:719-732.
69. Balasa B, Krahl T, Pastone G, Lee J, Tisch R, McDevitt HO, Sarvetnick N. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997;159:4620-4627.
70. + T cells. J Exp Med 2000;191:225-238.
71. Kenyon NS, Chatzipetrou M, Masetti M, Ranuncoli A, Oliveira M, Wagner JL, Kirk AD, Harlan DM, Burkly LC, Ricordi C. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci USA 1999;96:8132-8137.
72. + T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 2000;191:651-660.
73. Brenner B, Koppenhoefer U, Grassme H, Kun J, Lang F, Gulbins E. Evidence for a novel function of the CD40 ligand as a signaling molecule in T lymphocytes. FEBBS Lett 1997;417:301-306.
74. Shi L, Kraut RP, Aebersold R, Greenberg AH. A natural killer cell granule protein that induces DNA fragmentation and apoptosis. J Exp Med 1992;175:553-566.
75. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994;369:31-37.
76. Lowin B, Beermann F, Schmidt A, Tschopp J. A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1994;91:11571-11575.
77. Heusel J, Wesselschmidt R, Shresta S, Russell J, Ley T. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 1994;76:977-987.
78. Froelich C, Orth K, Turbov J, Seth P, Gottlieb R, Babior B, Shah GM, Bleackley RC, Dixit VM, Hanna W. New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and apoptosis. J Biol Chem 1996;271:29073-29079.
79. Shi L, Mai S, Israels S, Browne K, Trapani J, Greenberg A. Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. J Exp Med 1997;185:855-866.
80. Pinkoski MJ, Hobman M, Heibein JA, Tomaselli K, Li F, Seth P, Froelich CJ, Bleackley RC. Entry and trafficking of granzyme B in target cells during granzyme B-perforin-mediated apoptosis. Blood 1998;92:1040-1054.
81. Browne KA, Blink E, Sutton VR, Froelich CJ, Jans DA, Trapani JA. Cytosolic delivery of granzyme B by bacterial toxins: Evidence that endosomal disruption, in addition to transmembrane pore formation, is an important function of perforin. Mol Cell Biol 1999;19:8604-8615.
82. Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M, Barry M, Shostak I, Sawchuk T, Holmes CF, Gauldie J, Bleackley RC. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 2000;103:491-500.
83. Darmon A, Nicholson D, Bleackley R. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995;377:446-488.
84. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998;391:43-50.
85. Barry M, Heibein JA, Pinkoski MJ, Lee SF, Moyer RW, Green DR, Bleackley RC. Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol Cell Biol 2000;20:3781-3794.
86. Pinkoski MJ, Waterhouse NJ, Heibein JA, Wolf BB, Kuwana T, Goldstein JC, Newmeyer DD, Bleackley RC, Green DR. Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway. J Biol Chem 2001;276:12060-12067.
87. Heibein JA, Goping IS, Barry M, Pinkoski MJ, Shore GC, Green DR, Bleakley RC. Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J Exp Med 2000;192:1391-1402.
88. Sutton VR, Davis JE, Cancilla M, Johnstone RW, Ruefli AA, Sedelies K, Browne KA, Trapani JA. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med 2000;192:1403-1414.
89. Alimonti JB, Shi L, Baijal PK, Greenberg AH. Granzyme B induces BID-mediated cytochrome c release and mitochondrial permeability transition. J Biol Chem 2001;276:6974-6982.
90. Thomas DA, Scorrano L, Putcha GV, Korsmeyer SJ, Ley TJ. Granzyme B can cause mitochondrial depolarization and cell death in the absence of BID, BAX, and BAK. Proc Natl Acad Sci USA 2001;98:14985-14990.
91. Thomas DA, Du C, Xu M, Wang X, Ley TJ. DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity 2000;12:621-632.
92. Sharif-Askari E, Alam A, Rheaume E, Beresford PJ, Scotto C, Sharma K, Lee D, DeWolf WE, Nuttall ME, Lieberman J, Sekaly RP. Direct cleavage of the human DNA fragmentation factor-45 by granzyme B induces caspase-activated DNase release and DNA fragmentation. Embo J 2001;20:3101-3113.
93. Zhang D, Pasternack MS, Beresford PJ, Wagner L, Greenberg AH, Lieberman J. Induction of rapid histone degradation by the cytotoxic T lymphocyte protease Granzyme A. J Biol Chem 2001;276:3683-3690.
94. Zhang D, Beresford PJ, Greenberg AH, Lieberman J. Granzymes A and B directly cleave lamins and disrupt the nuclear lamina during granule-mediated cytolysis. Proc Natl Acad Sci USA 2001;98:5746-5751.
95. Shresta S, Graubert TA, Thomas DA, Raptis SZ, Ley TJ. Granzyme A initiates an alternative pathway for granule-mediated apoptosis. Immunity 1999;10:595-605.
96. Simon M, Hausmann M, Tran T, Ebnet K, Tschopp J, ThaHla R, Mullbacher A. In vitro- and Ex-derived cytolytic leukocytes from granzyme A X B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells. J Exp Med 1997;186:1781-1786.
97. Krensky AM. Granulysin: A novel antimicrobial peptide of cytolytic T lymphocytes and natural killer cells. Biochem Pharmacol 2000;59:317-320.
98. Kaspar AA, Okada S, Kumar J, Poulain FR, Drouvalakis KA, Kelekar A, Hanson DA, Kluck RM, Hitoshi Y, Johnson DE, Froelich CJ, Thompson CB, Newmeyer DD, Anel A, Clayberger C, Krensky AM. A distinct pathway of cell-mediated apoptosis initiated by granulysin. J Immunol 2001;167:350-356.
99. Irmler M, Thorme M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-195.
100. Li H, Zhu H, Xu C, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491-501.
101. Kim T, Zhao Y, Barber M, Kuharsky D, Yin X. Bid-induced cytochrome c release is mediated by a pathway independent of mitochondrial permeability transition pore and Bax. J Biol Chem 2000;275:39474-39481.
102. Deveraux Q, Reed T. IAP family proteins-suppressors of apoptosis. Genes Dev 1999;13:239-252.
103. Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M, Yao X, Puck JM, Straus SE, Lenardo MJ. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999;98:47-58.
104. Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K, Yagita H. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 1999;162:2639-2647.
105. Gura T. How TRAIL kills cancer cells, but not normal cells. Science 1997;277:768.
106. Jiang Y, Woronicz J, Liu W, Goeddel D. Prevention of constitutive TNF receptor 1 signaling by silence of death domains. Science 1999;283:543-546.
107. Siegel R, Chang F, Chun H, Lenardo M. The multifaceted role of fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000;1:469-474.
108. Kawahara A, YOhsawa, Matsumura H, Uchiyama Y, Nagata S. Caspase-independent cell killing by Fas-associated protein with death domain. J Cell Biol 1998;143:1353-1360.
109. Vercammen D, Brouckaert G, Denecker G, Van de Craen M, Declercq W, Fiers W, Vandenabeele P. Dual signaling of the Fas receptor: Initiation of both apoptotic and necrotic cell death pathways. J Exp Med 1998;188:919-930.
110. Villunger A, Huang D, Holler N, Tschopp J, Strasser A. Fas ligand-induced c-Jun kinase activation in lymphoid cells requires extensive receptor aggregation but is independent of DAXX, and Fas-mediated cell death does not involve DAXX, RIP or RAIDD. J Immunol 2000;165:1337-1343.
111. Li M, Berg A. Induction of necrotic-like cell death by tumor necrosis factor alpha and caspase inhibitors: Novel mechanism for killing virus-infected cells. J Virol 2000;74:7470-7477.
112. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-827.
113. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996;85:803-815.
114. Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, Krammer PH, Peter ME, Dixit VM. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996;271:4961-4965.
115. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME. Two CD95 (APO-1/Fas) signaling pathways. Embo J 1998;17:1675-1687.
116. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-490.
117. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53.
118. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42.
119. Hegde R, Srinivasula SM, Zhang Z, Wassell R, Mukattash R, Cilenti L, DuBois G, Lazebnik Y, Zervos AS, Fernandes-Alnemri T, Alnemri ES. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem 2002;277:432-438.
120. Kagi D, Odermatt B, Ohashi P, Zinkernagel R, Hengartner H. Development of insulitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity. J Exp Med 1996;183:2143-2152.
121. Seewaldt S, Thomas HE, Ejrnaes M, Christen U, Wolfe T, Rodrigo E, Coon B, Michelsen B, Kay TW, von Herrath MG. Virus-induced autoimmune diabetes: Most beta-cells die through inflammatory cytokines and not perforin from autoreactive (anti-viral) cytotoxic T-lymphocytes. Diabetes 2000;49:1801-1809.
122. + T cell-mediated insulin-dependent diabetes mellitus. J Immunol 1999;163:4335-4341.
123. Chervonsky A, Wang Y, Wong FS, Visintin I, Flavell RA, Janeway CA Jr, Matis LA. The role of Fas in autoimmune diabetes. Cell 1997;89:17-24.
124. Kagi D, Odermatt B, Seiler P, Zinkernagel R, Mak T, Hengartner H. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 1997;186:989-997.
125. Itoh N, Imagawa A, Hanafusa T, Waguri M, Yamamoto K, Iwahashi H, Moriwaki M, Nakajima H, Miyagawa J, Namba M, Makino S, Nagata S, Kono N, Matsuzawa Y. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J Exp Med 1997;186:613-618.
126. + T lymphocytes in transgenic nonobese diabetic mice. J Clin Invest 1999;103:1201-1209.
127. + T-lymphocytes. J Clin Invest 2000;105:459-468.
128. Stassi G, De Maria R, Trucco G, Rudert W, Testi R, Galluzzo A, Giordano C, Trucco M. Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 1997;186:1193-1200.
129. Heitmeier M, Scarim A, Corbett J. IFN-γ increases the sensitivity of islets of Langerhans for inducible nitric oxide synthase expression induced by interleukin 1. J Biol Chem 1997;272:13697-13704.
130. Moriwaki M, Itoh N, Miyagawa J, Yamamoto K, Imagawa A, Yamagata K, Iwahashi H, Nakajima H, Namba M, Nagata S, Hanafusa T, Matsuzawa Y. Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset Type I diabetes mellitus. Diabetologia 1999;42:1332-1340.
131. Garban H, Bonavida B. Nitroc Oxide inhibits the transcription repressor yin-yang 1 binding activity at the silencer region of the Fas promoter: A pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol 2001;167:75-81.
132. + T cells by a self-derived peptide. Nature (Lond.) 1995;378:295-298.
133. Brossart P, Bevan M. Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide. J Exp Med 1996;183:2449-2458.
134. Esser M, Krishnamurphy B, Braciale V. Distinct T cell receptor signaling requirements for perforin- or FasL-mediated cytotoxicity. J Exp Med 1996;183:1697-1706.
135. Lehmann C, Zeis M, Schmitz N, Uharek L. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 2000;96:594-600.
136. Medana I, Li Z, Flugel A, Tschopp J, Wekerle H, Neumann H. Fas ligand (CD95L) protects neurons against perforin-mediated T-lymphocyte cytotoxicity. J Immunol 2001;167:674-681.
137. Allison J, Strasser A. Mechanisms of beta cell death in diabetes: A minor role for CD95. Proc Natl Acad Sci USA 1998;95:13818-13822.
138. Pakala S, Chivetta M, Kelly C, Katz J. In autoimmune diabetes the transition from benighn to pernicious insulitis requires an inslet cell response to tumor necrosis factor x. J Exp Med 1999;189:1053-1062.
139. Thomas HE, Darwiche R, Corbett JA, Kay TW. Evidence that beta cell death in the nonobese diabetic mouse is Fas independent. J Immunol 1999;163:1562-1569.
140. Kim S, Kim KA, Hwang DY, Lee TH, Kayagaki N, Yagita H, Lee MS. Inhibition of autoimmune diabetes by Fas ligand: The paradox is solved. J Immunol 2000;164:2931-2936.
141. Su X, Hu Q, Kristan JM, Costa C, Shen Y, Gero D, Matis LA, Wang Y. Significant role for Fas in the pathogenesis of autoimmune diabetes. J Immunol 2000;164:2523-2532.
142. Green EA, Flavell RA. The temporal importance of TNF-alpha expression in the development of diabetes. Immunity 2000;12:459-469.
143. Walter U, Frantzke A, Sarukhan A, Zober C, von Boehmer H, Buer J, Lechner O. Monitoring gene expression of TNFR family members by beta-cells during development of autoimmune diabetes. Eur J Immunol 2000;30:1224-1232.
144. Yamada K, Takane-Gyotoku N, Ichikawa F, Inada C, Nokada K. Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 1996;39:1306-1312.
145. Bretz JD, Arscott PL, Myc A, Baker JR. Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells. J Biol Chem 1999;274:25433-25438.
146. Heitmeier MR, Arnush M, Scarim AL, Corbett JA. Pancreatic beta-Cell Damage Mediated by beta-Cell Production of Interleukin-1. A novel mechanism for virus-induced diabetes. J Biol Chem 2001;276:11151-11158.
147. Arnush M, Hitmeier M, Scarim A, Marino M, Manning P, Corbett J. IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 1998;102:516-526.
148. Arnush M, Scarim A, Hitmeier M, Kelly C, Corbett J. Potential role of resident islet macrophage activation in the initiation of of autoimmune diabetes. J Immunol 1998;160:2684-2691.
149. Dupraz P, Rinsch C, Pralong WF, Rolland E, Zufferey R, Trono D, Thorens B. Lentivirus-mediated Bcl-2 expression in beta TC-tet cells improves resistance to hypoxia and cytokine-induced apoptosi while preserving in vitro and in vivo control of insulin secretio. Gene Ther 1999;6:1160-1169.
150. Dupraz P, Cottet S, Hamburger F, Dolci W, Felley-Bosco E, Thorens B. Dominant negative MyD88 proteins inhibit interleukin-1beta/interferon-gamma-mediated induction of nuclear factor kap B-dependent nitrite production and apoptosis in beta cells. J Biol Chem 2000;275:37672-37678.
151. Thomas H, Darwiche R, Corbett J, Kay T. Interleukin-1 plus γ-interferon-induced pancreatic beta cell dysfunction is mediated by beta cell nitric oxide production. Diabetes 2002;51:311-316.
152. Cottet S, Dupraz P, Hamburger F, Dolci W, Jaquet M, Thorens B. SOCS-1 protein prevents Janus Kinase/STAT-dependent inhibition of beta cell insulin gene transcription and secretion in response to interferon-γ. J Biol Chem 2001;276:25862-25870.
153. Hoorens A, Stange G, Pavlovic D, Pipeleers D. Distinction between interleukin-1-induced necrosis and apoptosis of islet cells. Diabetes 2001;50:551-557.
154. Liu D, Pavlovic D, Chen MC, Flodstrom M, Sandler S, Eizirik DL. Cytokines induce apoptosis in beta-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (iNOS-/-). Diabetes 2000;49:1116-1122.
155. Mathews CE, Graser RT, Savinov A, Serreze DV, Leiter EH. Unusual resistance of ALR/Lt mouse beta cells to autoimmune destruction: Role for beta cell-expressed resistance determinants. Proc Natl Acad Sci USA 2001;98:235-240.
156. Hotta M, Tashiro F, Ikegami H, Niwa H, Ogihara T, Yodoi J, Miyazaki J. Pancreatic B cell-specific expression of thioredoxin, an antioxidative and antiapoptotoc protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med 1998;188:1445-1451.